Government Vaccine Virus 
Codon
JULY 28, 2025
Companies weigh market size, reimbursement potential (the likelihood insurers or governments will pay for the therapy), and the level of existing competition before deciding which vector to use for their gene therapy. AAV is a small virus that lacks a lipid membrane and carries a single-stranded piece of DNA stretching 4.7
The Pharma Data
JUNE 13, 2025
This meant putting the fundamentals of mRNA production directly into the hands of local innovators — a dramatic departure from previous models that kept much of vaccine production within a small number of firms in high-income settings. mRNA Technology Transfer Programme Moves Into Phase 2.0, 2026–2030).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JUNE 9, 2025
Temporary Recommendations: Strengthened Global Coordination and National Action The revised temporary recommendations, applicable until at least 20 August 2025, target all WHO Member States experiencing mpox virus (MPXV) transmission. Emergency Coordination WHO urges countries to strengthen political commitment at all levels of governance.
The Pharma Data
JUNE 27, 2025
The group, made up of virologists, epidemiologists, public health professionals, and biosafety specialists, has been working for over three years to shed light on one of the most pressing questions in modern global health: how did SARS-CoV-2, the virus responsible for COVID-19, first infect humans?
The Pharma Data
AUGUST 27, 2020
Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial. . Each patient was given two 100 microgram doses of the vaccine 28 days apart. These antibodies were higher than those seen in people who had recovered from the virus.
The Pharma Data
AUGUST 13, 2020
The UK government has signed deals for a further 90 million doses of coronavirus vaccine. The vaccines are being developed by the Belgian pharmaceutical company Janssen and the US biotech company Novavax. It means the UK has placed orders for six experimental vaccines, taking its potential stockpile to 340 million doses.
The Pharma Data
SEPTEMBER 25, 2020
A trial of a new vaccine that appears to train the immune system to fight coronavirus has begun in the UK. Early tests showed the jab, developed by US biotechnology company Novavax, leads to high levels of virus-fighting antibodies being produced. The trial on 10,000 people will now see if the vaccine can prevent people getting ill.
Expert insights. Personalized for you.
Let's personalize your content